Business
Cumberland Pharmaceuticals Announces Initiative to Expand Availability of Caldolor® to Help Treat High Fevers Associated With Coronavirus Infections
- Caldolor® is the Only Injectable NSAID Product FDA Approved to Treat Fever - Approved in Adult & Pediatric Patients (6 Months and Older) for Reduction of
About this update from Cumberland Pharmaceuticals Inc.
[{"type":"text","content":"- Caldolor® is the Only Injectable NSAID Product FDA Approved to Treat Fever\n - Approved in Adult & Pediatric Patients (6 Months and Older) for Reduction of Fever\n\n\nNASHVILLE, Tenn., March 31, 2020 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX) a specialty pharmaceutical company, today announced a national initiative to support hospitals and clinics that use Caldolor® (ibuprofen) injection for the treatment of patients with fever, severe hyperthermia and other symptoms associated with COVID-19 infections. \n\n \n \n \n \n \n \n\n \nCumberland's initiative includes the availability of special supply and financial arrangements, including favorable pricing and payment terms for hospitals and clinics to help ensure timely access to Caldolor during this healthcare crisis. For more information regarding this special access, contact Jim Herman, Cumberland's Senior Vice President National Accounts at [email protected].\n\"Reducing a very high fever can be particularly important in certain patients infected by COVID-19 and we are removing logistical and financial obstacles that might stand in the way of quickly getting health care providers a very effective, fast-acting and safe fever-reducing drug. We stand ready to take further actions required to assure that medical providers have access to an uninterrupted supply of this critical medication,\" said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals.\nBecause of the potential dangers of a high fever, recent guidelines from the Society of Critical Care Medicine suggest that clinicians consider using pharmacologic agents for controlling fever in COIVD-19 patients.1 High core body temperatures exceeding 101.3°F are associated with an increased incidence of convulsions, especially in children. Delirium can occur with temperatures between 103.1°F and 104.0°F, and coma with temperatures above 107.6°F.2\nEighty-eight percent of the patients in Wuhan, China infected with COVID-19 developed a fever during hospitalization. Of those patients, 26 percent were treated in an intensive care unit, and of those, approximately 60 percent developed respiratory failure and 31 percent developed shock. Prolonged hospital stays for those patients were not uncommon3,4. \nSome patients with high fevers are unable to swallow or retain oral antipyretic drugs and re...